Mia Demant1, Jonatan I Bagger1, Malte P Suppli1, Asger Lund1, Mette Gyldenløve1, Katrine B Hansen1, Kristine J Hare1, Mikkel Christensen1, David P Sonne1, Jens J Holst2, Tina Vilsbøll1,3, Filip K Knop1,3,4. 1. 1 Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, Hellerup, Denmark . 2. 2 Department of Biomedical Sciences and Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark . 3. 3 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark . 4. 4 Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen, Denmark .
Abstract
BACKGROUND: Fasting hyperglucagonemia can be detrimental to glucose metabolism in patients with type 2 diabetes (T2D) and may contribute to metabolic disturbances in obese and/or prediabetic subjects. However, the mechanisms underlying fasting hyperglucagonemia remain elusive. METHODS: We evaluated the interrelationship between fasting hyperglucagonemia and demographic and biochemical parameters in 106 patients with T2D (31% female, age: 57 ± 9 years [mean ± standard deviation; body mass index (BMI): 30.1 ± 4.4 kg/m2; fasting plasma glucose (FPG): 9.61 ± 2.39 mM; hemoglobin A1c (HbA1c): 57.1 ± 13.1 mmol/mol] and 163 nondiabetic control subjects (29% female; age: 45 ± 17 years; BMI: 25.8 ± 4.1 kg/m2; FPG: 5.2 ± 0.4 mM; and HbA1c: 35.4 ± 3.8 mmol/mol). Multiple linear regression analysis was applied using a stepwise approach with fasting plasma glucagon as dependent parameter and BMI, waist-to-hip ratio (WHR), blood pressure, hemoglobin A1c, FPG, and insulin concentrations as independent parameters. RESULTS: Fasting plasma glucagon concentrations were significantly higher among patients with T2D (13.5 ± 6.3 vs. 8.5 ± 3.8 mM, P < 0.001) together with HbA1c (P < 0.001), FPG (P < 0.001), and insulin (84.9 ± 56.4 vs. 57.7 ± 35.3 mM, P < 0.001). When adjusted for T2D, HbA1c and insulin were significantly positive determinants for fasting plasma glucagon concentrations. Furthermore, WHR comprised a significant positive determinant. CONCLUSIONS: We confirm that fasting plasma glucagon concentrations are abnormally high in patients with T2D, and show that fasting plasma glucagon concentrations are influenced by WHR (in addition to glycemic control and fasting plasma insulin concentrations), which may point to visceral fat deposition as an important determinant of increased fasting plasma glucagon concentrations.
BACKGROUND:Fasting hyperglucagonemia can be detrimental to glucose metabolism in patients with type 2 diabetes (T2D) and may contribute to metabolic disturbances in obese and/or prediabetic subjects. However, the mechanisms underlying fasting hyperglucagonemia remain elusive. METHODS: We evaluated the interrelationship between fasting hyperglucagonemia and demographic and biochemical parameters in 106 patients with T2D (31% female, age: 57 ± 9 years [mean ± standard deviation; body mass index (BMI): 30.1 ± 4.4 kg/m2; fasting plasma glucose (FPG): 9.61 ± 2.39 mM; hemoglobin A1c (HbA1c): 57.1 ± 13.1 mmol/mol] and 163 nondiabetic control subjects (29% female; age: 45 ± 17 years; BMI: 25.8 ± 4.1 kg/m2; FPG: 5.2 ± 0.4 mM; and HbA1c: 35.4 ± 3.8 mmol/mol). Multiple linear regression analysis was applied using a stepwise approach with fasting plasma glucagon as dependent parameter and BMI, waist-to-hip ratio (WHR), blood pressure, hemoglobin A1c, FPG, and insulin concentrations as independent parameters. RESULTS: Fasting plasma glucagon concentrations were significantly higher among patients with T2D (13.5 ± 6.3 vs. 8.5 ± 3.8 mM, P < 0.001) together with HbA1c (P < 0.001), FPG (P < 0.001), and insulin (84.9 ± 56.4 vs. 57.7 ± 35.3 mM, P < 0.001). When adjusted for T2D, HbA1c and insulin were significantly positive determinants for fasting plasma glucagon concentrations. Furthermore, WHR comprised a significant positive determinant. CONCLUSIONS: We confirm that fasting plasma glucagon concentrations are abnormally high in patients with T2D, and show that fasting plasma glucagon concentrations are influenced by WHR (in addition to glycemic control and fasting plasma insulin concentrations), which may point to visceral fat deposition as an important determinant of increased fasting plasma glucagon concentrations.
Entities:
Keywords:
hyperglucagonemia; liver-alpha cell feedback loop; nonalcoholic fatty liver disease; type 2 diabetes; waist-to-hip ratio
Authors: Cui Yang; Julia Brecht; Christel Weiß; Christoph Reissfelder; Mirko Otto; Jane N Buchwald; Georgi Vassilev Journal: Obes Surg Date: 2021-08-30 Impact factor: 3.479
Authors: Katharina Maruszczak; Konrad Radzikowski; Sebastian Schütz; Harald Mangge; Peter Bergsten; Anders Forslund; Hannes Manell; Thomas Pixner; Håkan Ahlström; Joel Kullberg; Katharina Mörwald; Daniel Weghuber Journal: Front Endocrinol (Lausanne) Date: 2022-09-05 Impact factor: 6.055
Authors: Kleopatra Alexiadou; Joyceline Cuenco; James Howard; Nicolai Jacob Wewer Albrechtsen; Ibiyemi Ilesanmi; Anna Kamocka; George Tharakan; Preeshila Behary; Paul R Bech; Ahmed R Ahmed; Sanjay Purkayastha; Robert Wheller; Matthieu Fleuret; Jens Juul Holst; Stephen R Bloom; Bernard Khoo; Tricia M-M Tan Journal: BMJ Open Diabetes Res Care Date: 2020-03
Authors: Martina Brunner; Othmar Moser; Reingard Raml; Maximilian Haberlander; Beate Boulgaropoulos; Barbara Obermayer-Pietsch; Eva Svehlikova; Thomas R Pieber; Harald Sourij Journal: Biomolecules Date: 2022-03-18